Viewing Study NCT05328102

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 3:37 AM

Ignite Modification Date: 2026-01-12 @ 6:11 AM

Study NCT ID: NCT05328102

Status: TERMINATED

Last Update Posted: 2024-04-30

First Post: 2022-04-04

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Sponsor: Xencor, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module